Immunomodulatory therapeutic strategies in stroke

Show simple item record

dc.contributor.author Malone, Kyle
dc.contributor.author Amu, Sylvie
dc.contributor.author Moore, Anne C.
dc.contributor.author Waeber, Christian
dc.date.accessioned 2019-11-20T05:12:18Z
dc.date.available 2019-11-20T05:12:18Z
dc.date.issued 2019-06-20
dc.identifier.citation Malone, K., Amu, S., Waeber, C. and Moore, A.C., 2019. Immunomodulatory Therapeutic Strategies in Stroke. Frontiers in Pharmacology, 10, (630). DOI:10.3389/fphar.2019.00630 en
dc.identifier.volume 10 en
dc.identifier.startpage 1 en
dc.identifier.endpage 21 en
dc.identifier.uri http://hdl.handle.net/10468/9111
dc.identifier.doi 10.3389/fphar.2019.00630 en
dc.description.abstract The role of immunity in all stages of stroke is increasingly being recognised, from the pathogenesis of risk factors to tissue repair, leading to the investigation of a range of immunomodulatory therapies. In the acute phase of stroke, proposed therapies include drugs targeting pro-inflammatory cytokines, matrix metalloproteinases, and leukocyte infiltration, with a key objective to reduce initial brain cell toxicity. Systemically, the early stages of stroke are also characterised by stroke-induced immunosuppression, where downregulation of host defences predisposes patients to infection. Therefore, strategies to modulate innate immunity post-stroke have garnered greater attention. A complementary objective is to reduce longer term sequelae, by focusing on adaptive immunity. Following stroke onset, the integrity of the blood-brain barrier is compromised, exposing central nervous system (CNS) antigens to systemic adaptive immune recognition, potentially inducing autoimmunity. Some pre-clinical efforts have been made to tolerise the immune system to CNS antigens pre-stroke. Separately, immune cell populations which exhibit a regulatory phenotype (T and B regulatory cells) have been shown to ameliorate post-stroke inflammation and contribute to tissue repair. Cell-based therapies, established in oncology and transplantation, could become a strategy to treat the acute and chronic stages of stroke. Furthermore, a role for the gut microbiota in ischemic injury has received attention. Finally, the immune system may play a role in remote ischemic preconditioning-mediated neuroprotection against stroke. The development of stroke therapies involving organs distant to the infarct site, therefore, should not be overlooked. This review will discuss the immune mechanisms of various therapeutic strategies, surveying published data and discussing more theoretical mechanisms of action that have yet to be exploited. en
dc.description.sponsorship GOIPG/2017/431; HRA-POR-2015-1236 en
dc.format.mimetype application/pdf en
dc.language.iso en en
dc.publisher Frontiers Media en
dc.relation.uri https://www.frontiersin.org/articles/10.3389/fphar.2019.00630
dc.rights © 2019 Malone, Amu, Moore and Waeber en
dc.rights.uri https://creativecommons.org/licenses/by/4.0/ en
dc.subject Stroke en
dc.subject Immunomodulation en
dc.subject Ischaemia en
dc.subject Immune en
dc.subject Therapy en
dc.subject Neuroinflammation en
dc.title Immunomodulatory therapeutic strategies in stroke en
dc.type Article (peer-reviewed) en
dc.internal.authorcontactother Christian Waeber, School of Pharmacy, University College Cork, Cork, Ireland. +353-21-490-3000 Email: c.waeber@ucc.ie en
dc.internal.availability Full text available en
dc.description.version Published Version en
dc.contributor.funder Irish Research Council en
dc.contributor.funder Health Research Board en
dc.contributor.funder Marie Curie en
dc.description.status Peer reviewed en
dc.identifier.journaltitle Frontiers in Pharmacology en
dc.internal.IRISemailaddress c.waeber@ucc.ie en
dc.identifier.articleid 630 en
dc.relation.project info:eu-repo/grantAgreement/EC/FP7::SP3::PEOPLE/631246/EU/Sphingosine kinase 2-mediated preconditioning in stroke/SPK AND STROKE en
dc.identifier.eissn 1663-9812


Files in this item

This item appears in the following Collection(s)

Show simple item record

© 2019 Malone, Amu, Moore and Waeber Except where otherwise noted, this item's license is described as © 2019 Malone, Amu, Moore and Waeber
This website uses cookies. By using this website, you consent to the use of cookies in accordance with the UCC Privacy and Cookies Statement. For more information about cookies and how you can disable them, visit our Privacy and Cookies statement